Seminars in Hematology
Volume 40, Issue 1 , Pages 79-86 , January 2003

Advanced-phase chronic myeloid leukemia

References 

  1. Anonymous . The antitumor effects and pharmacologic actions of harringtonine. Chin Med J. 1977;3:131–136
  2. Anonymous . Harringtonine in acute leukemias. Clinical analysis of 31 cases. Chin M J. 1977;3:319–324
  3. Beaupre DM, Kurzrock R. RAS and leukemia: from basic mechanisms to gene-directed therapy. J Clin Oncol. 1999;17:1071–1079
  4. Ben-Yehuda D, Krichevsky S, Rachmilewitz EA, et al.  Molecular follow-up of disease progression and interferon therapy in chronic myelocytic leukemia. Blood. 1997;90:4918–4923
  5. Branford S, Rudzki Z, Walsh S, et al.  High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood. 2002;99:3472–3475
  6. Canellos GP. Clinical characteristics of the blast phase of chronic granulocytic leukemia. Hematol Oncol Clin North Am. 1990;4:359–367
  7. Clift RA, Buckner CD, Thomas ED, et al.  Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. Blood. 1994;84:4368–4373
  8. Cortes J, Kantarjian H, O'Brien S, et al.  A pilot study of all-trans retinoic acid in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Leukemia. 1997;11:929–932
  9. Cortes J, Kantarjian H, Talpaz M, et al.  Treatment of chronic myelogenous leukemia with nucleoside analogs deoxycoformycin and fludarabine. Leukemia. 1997;11:788–791
  10. Cortes J, Talpaz M, O'Brien S, et al.  Suppression of cytogenetic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. J Clin Oncol. 1998;16:3279–3285
  11. Derderian PM, Kantarjian HM, Talpaz M, et al.  Chronic myelogenous leukemia in the lymphoid blastic phase: Characteristics, treatment response, and prognosis. Am J Med. 1993;94:69–74
  12. Druker BJ, Sawyers CL, Kantarjian H, et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038–1042
  13. Druker BJ, Talpaz M, Resta D, et al.  Clinical efficacy and safety of an ABL specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia. Blood. 1999;9(suppl 1, abstr):368a
  14. Druker BJ, Talpaz M, Resta DJ, et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031–1037
  15. Druker BJ, Tamura S, Buchdunger E, et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561–566
  16. Faderl S, Talpaz M, Estrov Z, et al.  Chronic myelogenous leukemia: Biology and therapy. Ann Intern Med. 1999;131:207–219
  17. Faderl S, Talpaz M, Estrov Z, et al.  The biology of chronic myeloid leukemia. N Engl J Med. 1999;341:164–172
  18. Feldman EJ, Seiter KP, Ahmed T, et al.  Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia. Leukemia. 1996;10:40–42
  19. Gambacorti-Passerini C, Barni R, le Coutre P, et al.  Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst. 2000;92:1641–1650
  20. Giles FJ, Cortes JE, Baker SD, et al.  Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. J Clin Oncol. 2001;19:762–771
  21. Giles FJ, Garcia-Manero G, Cortes JE, et al.  Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. J Clin Oncol. 2002;20:656–664
  22. Gorre ME, Mohammed M, Ellwood K, et al.  Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876–880
  23. Griffin JD, Todd RF, Ritz J, et al.  Differentiation patterns in the blastic phase of chronic myeloid leukemia. Blood. 1983;61:85–91
  24. Grove KL, Guo X, Liu SH, et al.  Anticancer activity of beta-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L configuration. Cancer Res. 1995;55:3008–3011
  25. Heathcote EJ, Shiffman ML, Cooksley WG, et al.  Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 2000;343:1673–1680
  26. Hofmann WK, Jones LC, Lemp NA, et al.  Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood. 2002;99:1860–1862
  27. Hoover RR, Mahon F-X, Melo JV, et al.  Overcoming STI571 resistance with the farnesyltransferase inhibitor SCH66336. Blood. 2001;98(suppl 1, abstr):617a
  28. Issa JP, Garcia-Manero G, Mannari R, et al.  Minimal effective dose of the hypomethylating agent decitabine in hematopoietic malignancies. Blood. 2001;98(suppl 1, abstr):594a
  29. Issa JP, Kantarjian H, Mohan A, et al.  Methylation of the ABL1 promoter in chronic myelogenous leukemia: Lack of prognostic significance. Blood. 1999;93:2075–2080
  30. Kano Y, Akutsu M, Tsunoda S, et al.  In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood. 2001;97:1999–2007
  31. Kantarjian H, O'Brien S, Cortes J, et al.  Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res. 2002;8:2167–2176
  32. Kantarjian HM, Cortes J, O'Brien S, et al.  Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood. 2002;99:3547–3553
  33. Kantarjian HM, Dixon D, Keating MJ, et al.  Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. 1988;61:1441–1446
  34. Kantarjian HM, Keating MJ, Estey EH, et al.  Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine. J Clin Oncol. 1992;10:772–778
  35. Kantarjian HM, O'Brien S, Smith TL, et al.  Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18:547–561
  36. Kantarjian HM, O'Brien SM, Keating M, et al.  Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia. 1997;11:1617–1620
  37. Kantarjian HM, Shan J, Smith T, et al.  Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase. Cancer. 2001;92:2501–2507
  38. Kantarjian HM, Smith TL, O'Brien S, et al.  Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med. 1995;122:254–261
  39. Kantarjian HM, Talpaz M, Kontoyiannis D, et al.  Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor. J Clin Oncol. 1992;10:398–405
  40. Kantarjian HM, Talpaz M, Smith TL, et al.  Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. J Clin Oncol. 2000;18:3513–3521
  41. Karp JE, Lancet JE, Kaufmann SH, et al.  Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase 1 clinical-laboratory correlative trial. Blood. 2001;97:3361–3369
  42. Kreil S, Muller MC, Lahaye T, et al.  Molecular and chromosomal mechanisms of resistance in CML patients after STI571 (Glivec) therapy. Blood. 2001;98(suppl 1, abstr 1823):435a
  43. le Coutre P, Tassi E, Varella-Garcia M, et al.  Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood. 2000;95:1758–1766
  44. Liu WM, Stimson LA, Joel SP. The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR-ABL positive chronic myeloid leukaemia cells: Synergistic interactions with anti-leukaemic agents. Br J Cancer. 2002;86:1472–1478
  45. Mahon FX, Deininger MW, Schultheis B, et al.  Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance. Blood. 2000;96:1070–1079
  46. Majlis A, Smith TL, Talpaz M, et al.  Significance of cytogenetic clonal evolution in chronic myelogenous leukemia. J Clin Oncol. 1996;14:196–203
  47. Mitelman F. The cytogenetic scenario of chronic myeloid leukemia. Leuk Lymphoma. 1993;11:11–15
  48. O'Brien S, Kantarjian H, Keating M, et al.  Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood. 1995;86:3322–3326
  49. O'Brien S, Kantarjian H, Koller C, et al.  Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. Blood. 1999;93:4149–4153
  50. Peters DG, Hoover RR, Gerlach MJ, et al.  Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood. 2001;97:1404–1412
  51. Sacchi S, Kantarjian HM, O'Brien S, et al.  Chronic myelogenous leukemia in nonlymphoid blastic phase: Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer. 1999;86:2632–2641
  52. Savage DG, Szydlo RM, Chase A, et al.  Bone marrow transplantation for chronic myeloid leukaemia: The effects of differing criteria for defining chronic phase on probabilities of survival and relapse. Br J Haematol. 1997;99:30–35
  53. Sawyers CL, Hochhaus A, Feldman E, et al.  Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study. Blood. 2002;99:3530–3539
  54. Scappini B, Onida F, Kantarjian H, et al.  In vitro effects of STI571-containing drug combinations on growth of Ph-positive myelogenous leukemia-derived cells. Blood. 2000;96(suppl 1, abstr):99a
  55. Schwartsmann G, Fernandes MS, Schaan MD, et al.  Decitabine (5-Aza-2'-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: Preliminary observations. Leukemia. 1997;11(suppl):S28–S31
  56. Sokal JE, Gomez GA, Baccarani M, et al.  Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia. Blood. 1988;72:294–298
  57. Speck B, Bortin MM, Champlin R, et al.  Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet. 1984;1:665–668
  58. Talpaz M, O'Brien S, Rose E, et al.  Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 2001;98:1708–1713
  59. Talpaz M, Silver RT, Druker BJ, et al.  Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99:1928–1937
  60. Thiesing JT, Ohno-Jones S, Kolibaba KS, et al.  Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood. 2000;96:3195–3199
  61. Thomas D, Cortes J, Giles FJ, et al.  Combination of Hyper-CVAD with imatinib mesylate for Philadelphia-positive adult acute lymphoblastic leukemia or chronic myelogenous leukemia in lymphoid blast phase. Blood. 2001;98(suppl 1, abstr 3340):803a
  62. Thomas D, Cortes J, O'Brien S, et al.  R115777, a farnesyl transferase inhibitor (FTI), has significant anti-leukemia activity in patients with chronic myeloid leukemia. Blood. 2001;98(suppl 1, abstr):727a
  63. Thomas D, Kantarjian H, O'Brien S, et al.  “Sudden” blastic phase (SBP) transformation in the first 2 years (YRS) of interferon-a (IFN) therapy (RX) for chronic phase (CP) chronic myelogenous leukemia (CML). Blood. 1998;92(suppl 1, abstr 1027):251a
  64. Topaly J, Zeller WJ, Fruehauf S. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia. 2001;15:342–347
  65. Wadhwa J, Szydlo RM, Apperley JF, et al.  Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. Blood. 2002;99:2304–2309
  66. Weisberg E, Griffin JD. Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients. Drug Resist Updates. 2001;4:22–28
  67. Wijermans P, Lubbert M, Verhoef G, et al.  Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients. J Clin Oncol. 2000;18:956–962
  68. Ye JS, Wang XH, Feng GH, et al.  Small-dose Harringtonine induces complete remission in patients with acute promyelocytic leukemia. Leukemia. 1988;2:427–429
  69. Zeuzem S, Feinman SV, Rasenack J, et al.  Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343:1666–1672
  70. Zion M, Ben-Yehuda D, Avraham A, et al.  Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia. Proc Natl Acad Sci USA. 1994;91:10722–19726

☆ Address reprint requests to Jorge Cortes, MD, Associate Professor of Medicine, Department of Leukemia, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 428, Houston, TX 77030.

PII: S0037-1963(03)70045-6

Seminars in Hematology
Volume 40, Issue 1 , Pages 79-86 , January 2003

Article Tools